{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:55:29Z","timestamp":1784285729262,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tokyo Foundation for Policy Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Continued receipt of Renin\u2013Angiotensin\u2013Aldosterone inhibitors in patients with COVID-19 has shown potential in producing better clinical outcomes. However, superiority between ACEi (angiotensin-converting enzyme inhibitors) and ARB (angiotensin II receptor blockers) regarding clinical outcomes in this setting remains unknown.\u00a0We retrospectively collected data on patients hospitalized for acute COVID-19 using the nationwide administrative database (Diagnosis and Procedure Combinations, DPC). The DPC data covered around 25% of all acute care hospitals in Japan. Patient outcomes, with focus on inpatient mortality, were compared between patients previously prescribed ACEi and those prescribed ARB. Comparisons based on crude, multivariate and propensity-score adjusted analysis were conducted. We examined a total of 7613 patients (ARB group, 6903; ACEi group 710). The ARB group showed lower crude in-hospital mortality, compared to the ACEi group (5% vs 8%; odds ratio, 0.65; 95% CI 0.48\u20130.87), however not in the multivariate-adjusted model (odds ratio, 0.95; 95% CI 0.69\u20131.3) or propensity-score adjusted models (odds ratio, 0.86; 95% CI 0.63\u20131.2).\u00a0ARB shows potential in reducing hospital stay duration over ACEi in patients admitted for COVID-19, but does not significantly reduce in-hospital mortality. Further prospective studies are needed to draw a definitive conclusion, but continuation of either of these medications is warranted to improve clinical outcomes.<\/jats:p>","DOI":"10.1038\/s41598-023-38838-8","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T15:02:20Z","timestamp":1689951740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparing clinical outcomes of ARB and ACEi in patients hospitalized for acute COVID-19"],"prefix":"10.1038","volume":"13","author":[{"given":"Seiji","family":"Hamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyosu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"38838_CR1","unstructured":"World Health Organization, WHO corona virus disease (COVID-19) dashboard. Accessed 25th April 2022."},{"key":"38838_CR2","unstructured":"World Health Organisation, Global excess deaths associated with COVID-19, January 2020\u2013December 2021."},{"issue":"6483","key":"38838_CR3","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367(6483), 1260\u20131263. https:\/\/doi.org\/10.1126\/science.abb2507 (2020).","journal-title":"Science"},{"issue":"2","key":"38838_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2), 271\u201380.e8. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052 (2020).","journal-title":"Cell"},{"issue":"5","key":"38838_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","volume":"17","author":"YY Zheng","year":"2020","unstructured":"Zheng, Y. Y. et al. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 17(5), 259\u2013260. https:\/\/doi.org\/10.1038\/s41569-020-0360-5 (2020).","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"38838_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1291\/hypres.31.553","volume":"31","author":"M Igase","year":"2008","unstructured":"Igase, M. et al. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens. Res. 31(3), 553\u2013559. https:\/\/doi.org\/10.1291\/hypres.31.553 (2008).","journal-title":"Hypertens. Res."},{"issue":"20","key":"38838_CR7","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/circulationaha.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario, C. M. et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111(20), 2605\u20132610. https:\/\/doi.org\/10.1161\/circulationaha.104.510461 (2005).","journal-title":"Circulation"},{"issue":"8","key":"38838_CR8","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1080\/10641963.2020.1783549[publishedOnlineFirst:20200622]","volume":"42","author":"M Sel\u00e7uk","year":"2020","unstructured":"Sel\u00e7uk, M. et al. Is the use of ACE inb\/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients? Clin. Exp. Hypertens. 42(8), 738\u2013742. https:\/\/doi.org\/10.1080\/10641963.2020.1783549 (2020).","journal-title":"Clin. Exp. Hypertens."},{"issue":"9","key":"38838_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","volume":"5","author":"N Mehta","year":"2020","unstructured":"Mehta, N. et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 5(9), 1020\u20131026. https:\/\/doi.org\/10.1001\/jamacardio.2020.1855 (2020).","journal-title":"JAMA Cardiol."},{"key":"38838_CR10","doi-asserted-by":"publisher","first-page":"e072175","DOI":"10.1136\/bmj-2022-072175","volume":"379","author":"MJ Jardine","year":"2022","unstructured":"Jardine, M. J. et al. Angiotensin receptor blockers for the treatment of covid-19: Pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. Bmj 379, e072175. https:\/\/doi.org\/10.1136\/bmj-2022-072175 (2022).","journal-title":"Bmj"},{"issue":"25","key":"38838_CR11","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1056\/NEJMoa2007621","volume":"382","author":"MR Mehra","year":"2020","unstructured":"Mehra, M. R. et al. Cardiovascular disease, drug therapy, and mortality in Covid-19. N. Engl. J. Med. 382(25), e102. https:\/\/doi.org\/10.1056\/NEJMoa2007621 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"38838_CR12","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/circresaha.120.317134[publishedOnlineFirst:20200417]","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang, P. et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ. Res. 126(12), 1671\u20131681. https:\/\/doi.org\/10.1161\/circresaha.120.317134 (2020).","journal-title":"Circ. Res."},{"issue":"3","key":"38838_CR13","doi-asserted-by":"publisher","first-page":"e213594","DOI":"10.1001\/jamanetworkopen.2021.3594","volume":"4","author":"R Baral","year":"2021","unstructured":"Baral, R. et al. Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: A systematic review and meta-analysis. JAMA Netw Open 4(3), e213594. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.3594 (2021).","journal-title":"JAMA Netw Open"},{"key":"38838_CR14","unstructured":"Medical Data Vision Co., Ltd. MDV Database."},{"key":"38838_CR15","doi-asserted-by":"publisher","first-page":"100365","DOI":"10.1016\/j.lanwpc.2021.100365","volume":"20","author":"Y Taniguchi","year":"2022","unstructured":"Taniguchi, Y. et al. Comparison of patient characteristics and in-hospital mortality between patients with COVID-19 in 2020 and those with influenza in 2017\u20132020: A multicenter, retrospective cohort study in Japan. Lancet Reg. Health West. Pac. 20, 100365. https:\/\/doi.org\/10.1016\/j.lanwpc.2021.100365 (2022).","journal-title":"Lancet Reg. Health West. Pac."},{"key":"38838_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010116","author":"R Inokuchi","year":"2021","unstructured":"Inokuchi, R. et al. Association between nafamostat mesylate and in-hospital mortality in patients with coronavirus disease 2019: A multicenter observational study. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm11010116 (2021).","journal-title":"J. Clin. Med."},{"issue":"3","key":"38838_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jacc.2004.09.073","volume":"45","author":"AH Wu","year":"2005","unstructured":"Wu, A. H. et al. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 45(3), 381\u2013387. https:\/\/doi.org\/10.1016\/j.jacc.2004.09.073 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"38838_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/icvts\/ivv235","volume":"21","author":"K Morita","year":"2015","unstructured":"Morita, K. et al. Outcomes after early or late timing of surgery for infective endocarditis with ischaemic stroke: A retrospective cohort study. Interact. Cardiovasc. Thorac. Surg. 21(5), 604\u2013609. https:\/\/doi.org\/10.1093\/icvts\/ivv235 (2015).","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"issue":"1","key":"38838_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40265-021-01639-2","volume":"82","author":"JG Rizk","year":"2022","unstructured":"Rizk, J. G. et al. Angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use associated with reduced mortality and other disease outcomes in US veterans with COVID-19. Drugs 82(1), 43\u201354. https:\/\/doi.org\/10.1007\/s40265-021-01639-2 (2022).","journal-title":"Drugs"},{"issue":"1","key":"38838_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/sj.jhh.1002101","volume":"21","author":"P Dandona","year":"2007","unstructured":"Dandona, P. et al. Angiotensin II and inflammation: The effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J. Hum. Hypertens. 21(1), 20\u201327. https:\/\/doi.org\/10.1038\/sj.jhh.1002101 (2007).","journal-title":"J. Hum. Hypertens."},{"issue":"5","key":"38838_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/ajh\/hpac001","volume":"35","author":"J Yin","year":"2022","unstructured":"Yin, J. et al. Effects of renin-angiotensin system inhibitors on mortality and disease severity of COVID-19 patients: A meta-analysis of randomized controlled trials. Am. J. Hypertens. 35(5), 462\u2013469. https:\/\/doi.org\/10.1093\/ajh\/hpac001 (2022).","journal-title":"Am. J. Hypertens."},{"key":"38838_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd9010015","author":"F Angeli","year":"2022","unstructured":"Angeli, F. et al. Renin angiotensin system blockers and risk of mortality in hypertensive patients hospitalized for COVID-19: An Italian Registry. J. Cardiovasc. Dev. Dis. https:\/\/doi.org\/10.3390\/jcdd9010015 (2022).","journal-title":"J. Cardiovasc. Dev. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38838-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38838-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38838-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T15:03:33Z","timestamp":1689951813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38838-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38838"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-38838-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"13 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11810"}}